Track Personalis, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Personalis, Inc. PSNL Open Personalis, Inc. in new tab

6.58 USD
EPS
-0.91
P/B
2.45
ROE
-35.02
Beta
2.11
Target Price
11.43 USD
Personalis, Inc. logo

Personalis, Inc.

🧾 Earnings Recap – Q3 2025

Personalis achieved significant growth in Q3 2025 with a 364% year-over-year increase in clinical tests, reflecting strong demand for its ultrasensitive NeXT Personal test, while adjusting revenue guidance due to biopharma project timing variability.

  • Revenue of $14.5 million surpassed expectations, driven by 4,388 clinical tests delivered in the quarter.
  • Growth in clinical adoption highlighted by over 700 physicians now ordering NeXT Personal.
  • Submitted additional coverage application for lung cancer, with three dossiers currently under review by MolDX.
  • Despite uneven biopharma spending, underlying demand for MRD technology remains strong, supporting long-term growth strategy.
  • Full-year revenue guidance adjusted to $68 million - $73 million, reflecting project timing volatility rather than demand changes.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 4, 2026
EPS-0.91
Book Value2.55
Price to Book2.45
Debt/Equity16.85
% Insiders26.956%
Growth
Revenue Growth0.03%
Estimates
Forward P/E-6.69
Forward EPS-0.93
Target Mean Price11.43

DCF Valuation

Tweak assumptions to recompute fair value for Personalis, Inc. (PSNL)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Personalis, Inc. Logo Personalis, Inc. Analysis (PSNL)

United States Health Care Official Website Stock

Is Personalis, Inc. a good investment? Personalis, Inc. (PSNL) is currently trading at 6.58 USD. Market analysts have a consensus price target of 11.43 USD. This suggests a potential upside from current levels.

Earnings Schedule: Personalis, Inc. is expected to release its next earnings report on May 4, 2026. The market consensus estimate for Forward EPS is -0.93.

Investor FAQ

Does Personalis, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Personalis, Inc.?

Personalis, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be May 4, 2026. The company currently has a trailing EPS of -0.91.

Company Profile

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and cancer patients. The company has strategic collaboration with Tempus AI, Inc. to bring testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.

Exchange Ticker
NGM (Sweden) PSNL

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion